Table 2.

Luteolin anti-aggregation property and protein deposition reduction in neurodegenerative disease models.

Relevant studies ↓	Molecule	Study samples	Neurodegenerative disease	Effect
Current Study Abuelnor Mohammed et al., 2023 (unpublished)	Luteolin	Neuroblastoma Cells	Huntington Disease	Reduction of soluble and aggregated htt protein.
Rehfeldt et al., 2022	Luteolin-7-O-Glucoside	Neurotoxin 6-OHDA-Induced Damage in vitro neurodegenerative model (SH-SY5Y)	Neuroblastoma cells	Monomers/aggregates were decreased in Luteolin-7-O-Glucoside-treated cells. vs. the non-treated cells
Ahmad et al., 2021	Luteolin	Amyloid-beta oligomers injected intracerebroventricularly into mice's brains	Alzheimer's mouse model	Amyloid-beta expression was reduced compared to the non-treated group.
Ali et al., 2019	Luteolin	Fruit fly model expressing human Aβ42	Alzheimer's disease	Deposition of amyloid plaque was less in the Alzheimer's disease fruit fly model.
Siddique et al., 2018	Luteolin	Transgenic fly (Drosophila) lines that express wild-type human synuclein	Parkinson’s disease	The presence of dopaminergic neurons in the Parkinson’s diseased flies exposed to various doses of luteolin. Also, the exposure to luteolin showed a dose-dependent increase in the dopamine content in the brains of Parkinson’s diseased flies.